Clinical Trials
15 trialsNCT06662786 2026-06-05
OrigAMI-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06750094 2026-06-05
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05253651 2026-06-04
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
NCT06469944 2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04210115 2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05945823 2026-04-09
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
NCT06780111 2026-03-31
MK-3475-06E
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06428409 2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04949256 2025-12-15
MK-7902-014
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT04456699 2024-10-29
LYNK-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01681472 2020-09-25
PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
Isofol Medical AB
Phase 1/2 Completed
NCT01789723 2020-01-23
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Acrotech Biopharma Inc.
Phase 1 Withdrawn
NCT01820091 2020-01-23
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Acrotech Biopharma Inc.
Phase 1 Withdrawn
NCT00865709 2014-12-11
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
Bayer
Phase 2 Completed